In early drug discovery, screening for drug-drug interactions (DDI) across seven major CYP enzymes is essential but traditionally slow and resource-intensive. This case study introduces BioDuro’s high-throughput solution: a fully validated 7-in-1 CYP Cocktail Assay that consolidates all required DDI assessments into a single incubation and rapid LC-MS/MS run.

Key Highlights

• Accelerated Screening: Replace seven separate assays with one integrated method, significantly reducing time and cost while maintaining regulatory-grade data quality.
• Robust Validation: Demonstrates consistent performance against individual substrate testing, ensuring reliable and reproducible results for confident decision-making.
• Ready for High-Throughput: Includes a rapid 2.1-minute analytical method capable of quantifying all metabolites in one injection—ideal for early-stage risk assessment and candidate optimization.

Download the full case study to discover how this streamlined approach can enhance your DDI screening strategy without compromising accuracy.